Encephalomyelitis Market Research Report- Global Forecast till 2027

Encephalomyelitis Market Research Report–Type (Acute Disseminated Encephalomyelitis, Encephalomyelitis Disseminata, Antimog Associated, AIDS Related Encephalomyelitis), Treatment (Drug Treatment, Surgery), End User (Hospital) - Global Forecast till 2027

ID: MRFR/Pharma/3446-HCR | | Region: Global | 85 pages

Encephalomyelitis Market Scenario


Encephalomyelitis is the condition of inflammation in the brain and spinal cord. The disease is caused by a number of factors including viral infection, bacteria and other. During last few years, the number of patients suffering from this disease is increasing due to which this disease has gained a considerable attention. According to the World Health Organization (WHO), 4.3 million people across the globe are affected by encephalomyelitis. The initial phase of disease is characterized by symptoms such as headache, fever, confusion, which in severe condition can led to hallucinations, trouble in speaking, and memory loss. A number of different types of drugs and vaccines are available in the market for the treatment. The patients suffering from autoimmune diseases & AIDS are the most commonly affected by the disease due to weak immune system. The encephalomyelitis market is majorly driven by the increasing prevalence of encephalomyelitis and rising number of patients suffering from autoimmune diseases & AIDS.  According to the American Autoimmune Related Diseases Association, in 2014, approximately 50 million people in the U.S. are suffering from autoimmune diseases. Additionally, during last decade, the number of patient suffering from AIDS in Asia Pacific region has elevated. Moreover, increasing geriatric population, government support and rapid developments in technology have fuelled the growth of the market. On the other hand, high cost of the treatment and unavailability of precise treatment may restrain the growth of the Encephalomyelitis Market.


The encephalomyelitis market is expected to grow at a CAGR of ~8.1 % during the forecast period 2017-2023. 


Intended Audience



  • Pharmaceutical and Biotechnological Companies

  • Research and Development (R&D) Companies

  • Neurological Companies

  • Hospitals and Clinics

  • Academic Institutes and Universities


Figure 1: Global Encephalomyelitis Market Share, by Types, 2016 (%) Encephalomyelitis Market


Sources: WHO, annual reports, press release, white paper, company presentation


Segmentations


The encephalomyelitis market is segmented on the basis of types, treatment and end users.


On the basis of types, the market is segmented into acute disseminated encephalomyelitis, encephalomyelitis disseminata, antiMOG associated encephalomyelitis, equine encephalomyelitis, AIDS related encephalomyelitis and others.


On the basis of treatment, the market is segmented into drug treatment, plasmapheresis, surgery, and others. Drug therapy is further segmented into antiviral medications, antibiotics, steroids, sedatives, NSAIDs, mood stabilizers, and others.


On the basis of end users, the market is segmented into hospital, clinics and others.


Regional Analysis


The Americas dominate the encephalomyelitis market owing to the increasing prevalence of patients with encephalomyelitis, and autoimmune diseases. Due to rapidly increasing patient population, governments have started supporting the manufacturers for the development of new and better drugs. Additionally, well developed technology, high healthcare expenditure, and strong government support for research & development have fuelled the growth of the market in this region.


Europe commands the second largest market for encephalomyelitis which is followed by Asia Pacific. Availability of funds, increasing need for better treatment options and strong government support drive the growth of the market in Europe. Germany, France & U.K holds the major share in the Europe market.


Asia Pacific is the fastest growing encephalomyelitis market owing to the increasing number of patients suffering from autoimmune diseases and AIDS. Additionally, rapidly growing economies and increasing healthcare expenditure will fuel the growth of the market.


On the other hand, the Middle East & Africa hold the least share of the market owing to less availability of funds, limited availability of medical facilities, and poor political conditions in Africa. The Middle East region holds the major share in the market owing to well developed technology, and high healthcare expenditure. On the other hand, Africa region shows the fastest growth due to availability of opportunities for the Encephalomyelitis Market growth.


Key Players


Some of key the players in the Encephalomyelitis Market Gare Bristol-Myers Squibb Company (U.S.), Sanofi (France), GlaxoSmithKline Plc. (U.K), Spectrum Pharmaceuticals Inc. (U.S.), Amgen, Inc. (U.S.), Merck & Co., Inc. (U.S.), Bayer AG (Germany), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd. (Switzerland), Eli Lilly and Company (U.S.), AstraZeneca Plc. (U.K), Janssen Biotech, Inc. (U.S.), AbbVie Inc. (U.S.), Takeda Pharmaceuticals (Japan), Immunomedics (U.S.), Pfizer, Inc. (U.S.), and Oncomed Pharmaceuticals (U.S.).


Research Methodology Global Encephalomyelitis Market


Sources: WHO, annual reports, press release, white paper, and company presentation


 



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :


High prevalence of autoimmune diseases and rising cases of encephalomyelitis can drive the global encephalomyelitis market growth.

Encephalomyelitis market is expected to exhibit 8.1% CAGR from 2017 to 2023.

High costs of treatment can impede the global encephalomyelitis market growth.

The Americas can lead the global encephalomyelitis market.

Takeda Pharmaceuticals, AbbVie Inc., Merck & Co., Inc., GlaxoSmithKline Plc., Eli Lilly and Company, Janssen Biotech, Inc., Oncomed Pharmaceuticals, Immunomedics, Novartis AG, Sanofi, AstraZeneca Plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Amgen, Inc., Bayer AG, Pfizer, Inc., and Spectrum Pharmaceuticals Inc. are major players of the global encephalomyelitis market.

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Encephalomyelitis Market, by Type

6.1 Introduction

6.2 Acute Disseminated Encephalomyelitis

Market Estimates & Forecast, 2020 – 2027

6.3 Encephalomyelitis Disseminata

Market Estimates & Forecast, 2020 – 2027

6.4 Deprivation & Occlusion Encephalomyelitis

Market Estimates & Forecast, 2020 – 2027

6.5 AntiMOG Associated Encephalomyelitis

Market Estimates & Forecast, 2020 – 2027

6.6 Equine Encephalomyelitis

Market Estimates & Forecast, 2020 – 2027

6.7 AIDS Related Encephalomyelitis

Market Estimates & Forecast, 2020 – 2027

6.8 Others

Chapter 7. Global Encephalomyelitis Market, by Treatment

7.1 Introduction

7.2 Drug Treatment

Market Estimates & Forecast, 2020 – 2027

7.2.1 Antiviral Medications

7.2.2 Antibiotics

7.2.3 Steroids

7.2.4 Sedatives

7.2.5 NSAIDs

7.2.6 Mood Stabilizers

7.2.7 Others

7.3 Plasmapheresis

Market Estimates & Forecast, 2020 – 2027

7.4 Surgery

Market Estimates & Forecast, 2020 – 2027

7.5 Others

Chapter 8. Global Encephalomyelitis Market, by End User

8.1 Introduction

8.2 Hospitals

Market Estimates & Forecast, 2020 – 2027

8.3 Clinics

Market Estimates & Forecast, 2020 – 2027

8.4 Others

Chapter 9. Global Encephalomyelitis Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 U.S.

9.2.1.1 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 U.K

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Bristol-Myers Squibb Company

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 Sanofi

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 GlaxoSmithKline Plc.

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Amgen, Inc

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Bayer AG

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.6 Novartis AG

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 F. Hoffmann-La Roche Ltd

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Pharmaceutical Industry

Chapter 13 Appendix

DATA TABLES

Table 1 Encephalomyelitis Industry Synopsis, 2020 – 2027

Table 2 Global Encephalomyelitis Market Estimates and Forecast, 2020 – 2027, (USD Million)

Table 3 Global Encephalomyelitis Market by Region, 2020 – 2027, (USD Million)

Table 4 Global Encephalomyelitis Market by Types, 2020 – 2027, (USD Million)

Table 5 Global Encephalomyelitis Market by Treatment, 2020 – 2027, (USD Million)

Table 6 Global Encephalomyelitis Market by End Users, 2020 – 2027, (USD Million)

Table 7 North America Encephalomyelitis Market by Types, 2020 – 2027, (USD Million)

Table 8 North America Encephalomyelitis Market by Treatment, 2020 – 2027, (USD Million)

Table 9 North America Encephalomyelitis Market by End Users, 2020 – 2027, (USD Million)

Table 10 US Market by Types, 2020 – 2027, (USD Million)

Table 11 US Encephalomyelitis Market by Treatment, 2020 – 2027, (USD Million)

Table 12 US Encephalomyelitis Market by End Users, 2020 – 2027, (USD Million)

Table 13 Canada Market by Types, 2020 – 2027, (USD Million)

Table 14 Canada Encephalomyelitis Market by Treatment, 2020 – 2027, (USD Million)

Table 15 Canada Encephalomyelitis Market by End Users, 2020 – 2027, (USD Million)

Table 16 South America Market by Types, 2020 – 2027, (USD Million)

Table 17 South America Encephalomyelitis Market by Treatment, 2020 – 2027, (USD Million)

Table 18 South America Encephalomyelitis Market by End Users, 2020 – 2027, (USD Million)

Table 19 Europe Market by Types, 2020 – 2027, (USD Million)

Table 20 Europe Encephalomyelitis Market by Treatment, 2020 – 2027, (USD Million)

Table 21 Europe Encephalomyelitis Market by End Users, 2020 – 2027, (USD Million)

Table 22 Western Europe Market by Types, 2020 – 2027, (USD Million)

Table 23 Western Europe Encephalomyelitis Market by Treatment, 2020 – 2027, (USD Million)

Table 24 Western Europe Encephalomyelitis Market by End Users, 2020 – 2027, (USD Million)

Table 25 Eastern Europe Market by Types, 2020 – 2027, (USD Million)

Table 26 Eastern Europe Encephalomyelitis Market by Treatment, 2020 – 2027, (USD Million)

Table 27 Eastern Europe Encephalomyelitis Market by End Users, 2020 – 2027, (USD Million)

Table 28 Asia Pacific Market by Types, 2020 – 2027, (USD Million)

Table 29 Asia Pacific Encephalomyelitis Market by Treatment, 2020 – 2027, (USD Million)

Table 30 Asia Pacific Encephalomyelitis Market by End Users, 2020 – 2027, (USD Million)

Table 31 Middle East & Africa Market by Types, 2020 – 2027, (USD Million)

Table 32 Middle East & Africa Encephalomyelitis Market by Treatment, 2020 – 2027, (USD Million)

Table 33 Middle East & Africa Encephalomyelitis Market by End Users, 2020 – 2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Encephalomyelitis Market

Figure 3 Segmentation Market Dynamics for Global Encephalomyelitis Market

Figure 4 Global Encephalomyelitis market Share, by type 2020

Figure 5 Global Encephalomyelitis market Share, by Treatment 2020

Figure 6 Global Encephalomyelitis Market Share, by End Users, 2020

Figure 7 Global Encephalomyelitis Market Share, by Region, 2020

Figure 8 North America Encephalomyelitis Market Share, by Country, 2020

Figure 9 Europe Encephalomyelitis Market Share, by Country, 2020

Figure 10 Asia Pacific Encephalomyelitis Market Share, by Country, 2020

Figure 11 Middle East & Africa Encephalomyelitis Market Share, by Country, 2020

Figure 12 Global Encephalomyelitis Market: Company Share Analysis, 2020 (%)

Figure 13 Bristol-Myers Squibb Company: Key Financials

Figure 14 Bristol-Myers Squibb Company: Segmental Revenue

Figure 15 Bristol-Myers Squibb Company: Geographical Revenue

Figure 16 Sanofi: Key Financials

Figure 17 Sanofi: Segmental Revenue

Figure 18 Sanofi: Geographical Revenue

Figure 19 GlaxoSmithKline Plc.: Key Financials

Figure 20 GlaxoSmithKline Plc.: Segmental Revenue

Figure 21 GlaxoSmithKline Plc.: Geographical Revenue

Figure 22 Amgen, Inc: Key Financials

Figure 23 Amgen, Inc: Segmental Revenue

Figure 24 Amgen, Inc: Geographical Revenue

Figure 25 Bayer AG: Key Financials

Figure 26 Bayer AG: Segmental Revenue

Figure 27 Bayer AG: Geographical Revenue

Figure 28 Novartis AG : Key Financials

Figure 29 Novartis AG : Segmental Revenue

Figure 30 Novartis AG : Geographical Revenue

Figure 31 F. Hoffmann-La Roche Ltd: Key Financials

Figure 32 F. Hoffmann-La Roche Ltd: Segmental Revenue

Figure 33 F. Hoffmann-La Roche Ltd: Geographical Revenue